Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

17.60 -0.86 (-4.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
From Novocure
Via Business Wire
Novocure to Report Second Quarter 2025 Financial Results
From Novocure
Via Business Wire
Demystifying NovoCure: Insights From 4 Analyst Reviews
Via Benzinga
Earnings Scheduled For April 24, 2025
Via Benzinga
NovoCure's Earnings: A Preview
Via Benzinga
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Via The Motley Fool
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
Via Benzinga
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial. 
Via Benzinga
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
Via The Motley Fool
Earnings Scheduled For February 27, 2025
Via Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
Why NovoCure Stock Skyrocketed This Week
Via The Motley Fool
Topics Earnings Stocks
Why NovoCure Stock Leaped 4% Higher Today
Via The Motley Fool
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs. 
Via Benzinga
Topics World Trade
NovoCure Surpasses Q1 Expectations
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Novocure Reports First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Why NovoCure Stock Was Withering on Wednesday
Via The Motley Fool
Novocure to Report First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
From Novocure
Via Business Wire
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion. 
Via Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.